Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 916

1.

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.

Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J.

Oncologist. 2020 Jan 14. doi: 10.1634/theoncologist.2019-0637. [Epub ahead of print]

2.

Use of a bioengineered antioxidant in mouse models of metabolic syndrome.

Griffin DM, Bitner BR, Criss Ii Z, Marcano D, Berlin JM, Kent TA, Tour JM, Samson SL, Pautler RG.

Expert Opin Investig Drugs. 2020 Jan 15. doi: 10.1080/13543784.2020.1716216. [Epub ahead of print]

PMID:
31937152
3.

Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.

Varghese AM, Cardin DB, Hersch J, Benson A, Hochster HS, Makris L, Hamada K, Berlin J, Saltz LB.

Clin Cancer Res. 2020 Jan 10. pii: clincanres.2743.2019. doi: 10.1158/1078-0432.CCR-19-2743. [Epub ahead of print]

4.
5.
6.
7.

Learning from electronic health records across multiple sites: A communication-efficient and privacy-preserving distributed algorithm.

Duan R, Boland MR, Liu Z, Liu Y, Chang HH, Xu H, Chu H, Schmid CH, Forrest CB, Holmes JH, Schuemie MJ, Berlin JA, Moore JH, Chen Y.

J Am Med Inform Assoc. 2019 Dec 9. pii: ocz199. doi: 10.1093/jamia/ocz199. [Epub ahead of print]

PMID:
31816040
8.

Colloidal Capsules Assembled from Gold Nanoparticles Using Small-Molecule Hydrophobic Cross-linkers.

Zhang Y, Abidi W, Berlin JM.

Langmuir. 2019 Dec 31;35(52):17037-17045. doi: 10.1021/acs.langmuir.9b01903. Epub 2019 Dec 19.

PMID:
31804093
9.
10.
11.

Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop.

Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, Ashby D, Emsley R, Fergusson DA, Walters SJ, Wilson EC, MacLennan G, Stallard N, Rothwell JC, Bland M, Brown L, Ramsay CR, Cook A, Armstrong D, Altman D, Vale LD.

Health Technol Assess. 2019 Oct;23(60):1-88. doi: 10.3310/hta23600.

12.

Correction to: Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidance.

Sones W, Julious SA, Rothwell JC, Ramsay CR, Hampson LV, Emsley R, Walters SJ, Hewitt C, Bland M, Fergusson DA, Berlin JA, Altman D, Vale LD, Cook JA.

Trials. 2019 Oct 24;20(1):602. doi: 10.1186/s13063-019-3809-2.

13.

A community approach to engaging Gypsy and Travellers' in cancer services.

Smith D, Newton P, Berlin J, Barrett S.

Health Promot Int. 2019 Oct 16. pii: daz103. doi: 10.1093/heapro/daz103. [Epub ahead of print]

PMID:
31617902
14.

System Failure: Houston Practices Fight WellCare for Payment.

Berlin J.

Tex Med. 2019 Oct 1;115(10):28-29.

PMID:
31613383
15.

No Docs of All Trades: Ruling Reinforces Expert Witness Reforms.

Berlin J.

Tex Med. 2019 Oct 1;115(10):42-44.

PMID:
31613382
16.

A guide to prospective meta-analysis.

Seidler AL, Hunter KE, Cheyne S, Ghersi D, Berlin JA, Askie L.

BMJ. 2019 Oct 9;367:l5342. doi: 10.1136/bmj.l5342. No abstract available.

PMID:
31597627
17.

What Are Factorial Experiments and Why Can They Be Helpful?

Berlin JA.

JAMA Netw Open. 2019 Sep 4;2(9):e1911917. doi: 10.1001/jamanetworkopen.2019.11917. No abstract available.

PMID:
31553465
18.

Boarding of Mentally Ill Patients in Emergency Departments: American Psychiatric Association Resource Document.

Nordstrom K, Berlin JS, Nash SS, Shah SB, Schmelzer NA, Worley LLM.

West J Emerg Med. 2019 Jul 22;20(5):690-695. doi: 10.5811/westjem.2019.6.42422. Review.

19.

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.

Kim SB, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, Sommer A, Osada M, Reetz F, Laurent D, Wittemer-Rump S, Berlin J.

Target Oncol. 2019 Oct;14(5):591-601. doi: 10.1007/s11523-019-00670-4.

20.

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.

Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, Schuemie MJ, Ryan PB, Sun D, Freedman A, Alba M, Lind J, Meininger G, Berlin JA, Rosenthal N.

Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1620-1628. doi: 10.1002/pds.4887. Epub 2019 Aug 27.

21.

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.

Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC.

Ann Surg Oncol. 2019 Dec;26(13):4489-4497. doi: 10.1245/s10434-019-07685-1. Epub 2019 Aug 15.

PMID:
31418130
22.

Insurance: Network Solutions.

Berlin J.

Tex Med. 2019 Aug 1;115(8):18-19.

PMID:
31369142
23.

Opioids and Pharmacy: PMP Extension Granted.

Berlin J.

Tex Med. 2019 Aug 1;115(8):22.

PMID:
31369140
24.

Medicaid: Reforms, But No Raise.

Berlin J.

Tex Med. 2019 Aug 1;115(8):23.

PMID:
31369139
25.

Scope of Practice: Shot Down.

Berlin J.

Tex Med. 2019 Aug 1;115(8):24.

PMID:
31369138
26.

Swinging For Fairness: Law Creates New Ballgame for Surprise Billing.

Berlin J.

Tex Med. 2019 Aug 1;115(8):30-31.

PMID:
31369134
27.
28.
29.

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.

Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Gracian AC, Mangel L, Fernandez EE, Deming DA, Ramanathan RK, Torres AH, Sullivan D, Luo Y, Berlin JD.

Br J Cancer. 2019 Aug;121(5):429-430. doi: 10.1038/s41416-019-0528-0.

30.

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ.

Invest New Drugs. 2019 Jul 23. doi: 10.1007/s10637-019-00824-1. [Epub ahead of print]

PMID:
31338636
31.
32.

United Healthcare Cuts Consults.

Berlin J.

Tex Med. 2019 Jul 1;115(7):36-37.

PMID:
31334825
33.

A randomized trial provided new evidence on the accuracy and efficiency of traditional vs. electronically annotated abstraction approaches in systematic reviews.

Li T, Saldanha IJ, Jap J, Smith BT, Canner J, Hutfless SM, Branch V, Carini S, Chan W, de Bruijn B, Wallace BC, Walsh SA, Whamond EJ, Murad MH, Sim I, Berlin JA, Lau J, Dickersin K, Schmid CH.

J Clin Epidemiol. 2019 Nov;115:77-89. doi: 10.1016/j.jclinepi.2019.07.005. Epub 2019 Jul 11.

34.

Medicare Muzzle? New Rules May Make Physicians Reluctant to Speak Up.

Berlin J.

Tex Med. 2019 Jun 1;115(6):42-45.

PMID:
31260545
35.
36.
37.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.

Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21.

38.

Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update.

Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, Mumber M, Schulick R, Zeh HJ, Katz MHG.

J Clin Oncol. 2019 Aug 10;37(23):2082-2088. doi: 10.1200/JCO.19.00946. Epub 2019 Jun 10.

PMID:
31180816
39.

PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.

Roberts J, Salaria SN, Cates J, Wang Y, Vnencak-Jones C, Berlin J, Shi C.

Am J Clin Pathol. 2019 Aug 1;152(3):384-391. doi: 10.1093/ajcp/aqz052.

PMID:
31152546
40.

Comment on "How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias".

Schuemie MJ, Madigan D, Ryan PB, Reich C, Suchard MA, Berlin JA, Hripcsak G.

Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):1032-1033. doi: 10.1002/pds.4798. Epub 2019 May 8. No abstract available.

PMID:
31066478
41.

Is Your Board Certification Safe?

Berlin J.

Tex Med. 2018 Jun 1;114(6):38-40.

PMID:
31009543
42.

Texas Physicians Adjust to Electronic Communication.

Berlin J.

Tex Med. 2018 Jun 1;114(6):26-30.

PMID:
31009542
43.

Federal Bill Would Limit Opioid Scrips for Acute Pain.

Berlin J.

Tex Med. 2018 Jun 1;114(6):42-44.

PMID:
31009539
44.
45.

Medicine's Monthly Bullhorn: First Tuesdays at the Capitol.

Berlin J.

Tex Med. 2019 Apr 1;115(4):23-27.

PMID:
30995336
46.

Closing a Loophole: Medicine Works to Clarify MOC Law.

Berlin J.

Tex Med. 2019 Mar 1;115(3):36-38.

PMID:
30995332
47.

Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.

Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N.

J Clin Oncol. 2019 Jun 1;37(16):1436-1447. doi: 10.1200/JCO.19.00281. Epub 2019 Apr 15.

PMID:
30986117
48.

How Confident Should We Be About Recommendations Based on Network Meta-analyses?

Berlin JA.

Ann Intern Med. 2019 Apr 16;170(8):571-572. doi: 10.7326/M19-0754. Epub 2019 Mar 26. No abstract available.

PMID:
30909296
49.

A Research Agenda for Assessment and Management of Psychosis in Emergency Department Patients.

Peltzer-Jones J, Nordstrom K, Currier G, Berlin JS, Singh C, Schneider S.

West J Emerg Med. 2019 Mar;20(2):403-408. doi: 10.5811/westjem.2019.1.39263. Epub 2019 Feb 19. Review.

50.

Out in the Cold: Health Plan Blamed For Major Prompt-Pay Mess.

Berlin J.

Tex Med. 2019 Mar 1;115(3):20-25.

PMID:
30855697

Supplemental Content

Loading ...
Support Center